🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

XOMA Royalty Corp XOMA R2KPHARMA

Healthcare · Biotechnology · United States
https://www.xoma.com
Company Profile ↓
$40.17
+0.00% 1Y
Mkt Cap$710.16M
P/E25.59
P/B5.15
52W High$40.17
52W Low$40.17
Book Value$7.79
EPS (TTM)$1.57

Company Overview

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California. As of July 14, 2026, XOMA Royalty Corporation operates as a subsidiary of Ligand Pharmaceuticals Incorporated.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 34.2%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 18.9%.

Consistent Profit Growth

Net profit has compounded at 95.1% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 24.6% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 69.6%.

Recent Developments

  • Dec 2025 Revenue of $11.66M (+14.1% YoY); net profit $31.71M.
  • Trailing 12 Months Year-on-year growth — revenue -22.6%, earnings +207.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 24.6%, profit CAGR 95.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:24.60%
1 Year:-22.60%

Compounded Profit Growth

5 Years:95.14%
1 Year:207.90%

Stock Price Performance

1 Year:+0.00%
6 Months:-
3 Months:-
1 Month:-

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
Price Performance
1Y+0.00%
Valuation vs Sector

P/E of 25.59 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 34.2%.
  • Excellent profit margin of 69.6%.
  • Compounding revenue at 24.6% over 5 years.
  • Profit CAGR of 95.1% over 5 years.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
25.59
Industry PE
25.17
Forward P/E
18.77
PEG Ratio
-
Book Value
$7.79
Price to Book
5.15
P/S
14.63
EV/EBITDA
67.81
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
24.60%
Profit 5Y
95.14%
Revenue (YoY)
-22.60%
Earnings (YoY)
207.90%

Profitability & Returns

ROCE
18.85%
ROE
34.23%
ROA
1.28%
Profit Margin
69.63%
Op Margin
-3.90%
Gross Margin
99.04%
EPS (Latest Qtr)
$0.17
EPS (TTM)
$1.57

Balance Sheet & Liquidity

Debt/Equity
1.10
Quick Ratio
3.31
Current Ratio
3.59
Debt
$124.73M
Total Assets
$271.86M
Current Assets
$118.75M
Working Capital
$82.44M

Ownership

Promoter Holding
2.33%
Chg in Prom Hold
-
FII / Inst Holding
85.33%
Chg in FII Hold
0.29%

Financial Snapshot

Enterprise Value
$710.16M
Total Revenue (TTM)
$48.55M
EBITDA
$8.29M
Free Cash Flow
$-13.07M
Operating Cash Flow
$6.79M
Shares Outstanding
17.68M
Gross Margin
99.04%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 XOMA XOMA Royalty Corp R2KPHARMA 40.17 25.59 $710.16M 0.00% 18.85% 34.23% 24.60% 95.14%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -------10.78M36.07M-401.00K2.34M775.00K-8.03M625.00K8.53M-500.00K53.00K200.00K-19.00K525.00K550.00K2.75M525.00K25.00K-1.12M225.00K1.00M5.03M25.00K-4.32M5.38M532.00K1.43M310.00K
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses ------------------------------------1.61M776.00K1.86M-750.00K790.00K
Operating Income -23.68M28.74M-13.99M-18.02M-12.09M-17.46M-10.92M1.31M28.65M-2.01M-5.14M-2.99M-5.31M-3.42M1.94M-4.71M2.89M-4.00M-5.62M-3.15M-2.69M23.87M-6.43M-3.06M-3.35M-2.06M-4.77M-4.37M-10.17M-5.96M-5.79M-7.00M-10.08M-15.64M-5.93M4.60M-1.33M2.18M-480.00K
EBITDA -----------------------------------6.38M13.09M18.28M10.07M8.72M
Interest Expense -----------------------------------3.47M3.24M3.30M3.03M3.36M
Pretax Income -----------------------------------2.37M9.19M14.10M6.16M4.47M
Tax Provision -----------------------------------0-49.00K54.00K1.00K
Net Income -480.00K25.35M-8.37M-15.16M-12.53M-17.48M-10.71M285.00K26.34M-1.32M-3.81M-1.95M-4.58M-3.01M3.23M-4.07M3.18M-4.32M-4.76M-3.53M-1.08M22.67M-7.37M-2.24M-4.44M-2.28M-4.67M-4.18M-9.81M-5.40M-5.51M-8.60M15.98M-17.24M-2.37M9.19M14.05M6.10M4.46M
Diluted EPS -0.084.24-1.40-2.52-2.08-2.89-2.370.021.98-0.16-0.46-0.23-0.55-0.350.21-0.470.20-0.49-0.49-0.33-0.101.32-0.70-0.31-0.51-0.32-0.53-0.48-0.98-0.59-0.60-0.860.84-1.59-0.060.440.700.260.17
R&D Expense 17.56M-13.61M13.70M8.67M-3.99M2.92M307.00K-432.00K376.00K637.00K-256.00K724.00K143.00K-62.00K38.00K34.00K-61.00K38.00K30.00K56.00K40.00K29.00K54.00K39.00K25.00K33.00K1.16M817.00K-1.29M69.00K69.00K-49.00K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 98.43M33.64M58.20M33.78M35.45M18.87M55.45M5.56M52.43M5.07M17.28M27.94M-6.03M4.76M10.22M11.66M
Cost of Revenue -----------------
Gross Profit -----------------
Operating Expenses -------------23.44M28.22M50.20M276.00K
Operating Income 12.96M-67.10M-33.95M-56.62M-58.20M-81.83M-39.72M-61.56M17.03M-16.86M-3.88M12.42M--17.41M-23.46M-39.98M11.38M
EBITDA --------------17.02M-39.36M-5.42M47.82M
Interest Expense -------------0569.00K13.84M13.03M
Pretax Income --------------17.12M-40.83M-19.48M31.82M
Tax Provision --------------15.00K0-5.66M103.00K
Net Income 550.00K-68.76M-32.74M-71.06M-124.06M-38.30M-20.61M-53.53M14.60M-13.34M-1.98M13.30M--17.10M-40.83M-13.82M31.71M
Diluted EPS ----1.10-1.43-13.49-3.50-8.890.73-1.59-0.230.78--1.98-4.04-1.651.46
R&D Expense 58.13M77.41M68.14M68.47M74.85M80.75M70.85M44.23M7.88M1.68M1.25M170.00K171.00K153.00K143.00K2.88M1.71M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --74.25M78.04M105.68M134.78M89.40M74.88M28.68M44.94M63.78M95.72M125.28M-140.38M234.30M221.28M272.70M
Current Assets --------------61.25M169.31M125.60M117.26M
Cash & Equivalents 9.51M23.91M37.30M48.34M45.34M101.66M78.44M65.77M25.74M43.47M45.78M---57.83M153.29M101.65M82.91M
Inventory ------------------
Receivables --------------1.00K1.00M1.84M4.90M
Total Liabilities --50.66M63.02M84.21M138.77M86.30M77.19M75.89M39.15M45.00M51.74M38.86M-16.37M145.58M159.38M188.76M
Current Liabilities --35.53M20.63M23.83M29.64M36.25M23.30M32.51M7.42M5.70M8.88M12.30M-6.82M19.50M24.37M34.82M
Long Term Debt --13.69M33.52M37.65M35.15M16.29M42.76M25.31M14.57M21.69M27.09M12.76M--118.52M106.88M96.45M
Total Debt --------------34.00K124.45M119.20M131.56M
Total Equity -31.40M17.53M23.59M15.01M21.47M-3.99M3.10M-2.31M-47.21M5.79M18.79M43.99M86.42M-124.01M88.72M61.90M83.94M
Shares Outstanding --------------11.45M11.50M11.95M11.86M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 7.43M-52.54M-29.06M-40.77M-45.91M---2.69M-12.64M-285.00K10.09M--12.88M-18.16M-13.75M2.87M
Investing Cash Flow 10.57M-339.00K-3.30M-42.02M18.84M---1.61M-15.01M-19.30M-209.00K--20.22M-711.00K-28.26M50.89M
Financing Cash Flow -3.61M66.27M43.98M79.78M83.39M---13.26M29.94M30.49M19.79M--4.45M120.59M-11.13M-26.46M
Capital Expenditure -270.00K-339.00K-3.30M-2.51M-1.17M-325.00K-430.00K-59.00K-8.00K-6.00K--9.00K--15.25M-17.00K-20.00K-20.73M
Free Cash Flow 7.17M-52.88M-32.37M-43.27M-47.08M---2.68M-12.65M-10.08M--28.13M-18.18M-13.77M-17.85M
Net Change in Cash --------------37.55M101.72M-53.13M27.29M
Share Buybacks ---------------13.00K16.04M
Dividends Paid ------------3.50M5.47M5.47M5.47M5.47M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------
Operating Margin % 13.2%-199.5%-58.3%-167.6%-164.2%-433.8%-71.6%-1,106.4%32.5%-332.6%-22.5%44.4%--288.9%-493.1%-391.2%97.6%
Net Margin % 0.6%-204.4%-56.3%-210.4%-349.9%-203.0%-37.2%-962.1%27.8%-263.3%-11.5%47.6%--283.8%-858.2%-135.2%272.0%
ROE % 3.1%-291.5%-218.1%-331.0%3,111.6%-1,235.9%892.4%113.4%252.3%-71.0%-4.5%15.4%--13.8%-46.0%-22.3%37.8%
ROCE % --173.3%-59.1%-69.2%-55.4%-153.9%-77.0%1,607.7%45.4%-29.0%-4.5%11.0%--13.0%-10.9%-20.3%4.8%

Shareholding Pattern

Insiders
2.33%
Institutions
85.33%
Public Float
87.37%

Top Institutional Holders

#Holder% HeldSharesValue
1 BVF Inc. 14.65% 2.59M $104.05M
2 Morgan Stanley 9.63% 1.70M $68.38M
3 FMR, LLC 7.37% 1.30M $52.34M
4 Blackrock Inc. 3.66% 646.91K $25.99M
5 Woodline Partners LP 3.62% 640.00K $25.71M
6 Vanguard Capital Management LLC 3.11% 549.80K $22.09M
7 Opaleye Management Inc. 1.70% 300.00K $12.05M
8 GW&K Investment Management, LLC 1.31% 232.14K $9.33M
9 Geode Capital Management, LLC 1.30% 229.77K $9.23M
10 Millennium Management Llc 1.16% 204.92K $8.23M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for XOMA

Yahoo Finance Sat, 27 Jun 2026

XOMA Royalty (XOMA) Stock Fair Value Falls After Ligand Agrees Cash Acquisition

The fair value price target for XOMA Royalty has been reset from US$65.75 to US$39.00, now aligned with the agreed all cash acquisition price. Analysts are centering their narratives on this US$39 level as the key reference point for both v…

Yahoo Finance hu, 16 Jul 2026

Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings

Ligand Pharmaceuticals stock has delivered a very large 338.7% return over the past three years, yet its valuation signals are split, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model suggesting the shares trade below…

Yahoo Finance Fri, 12 Jun 2026

XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date

EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced that its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s (i)…

Yahoo Finance Fri, 15 May 2026

Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates

Oncobiologics (OTLK) delivered earnings and revenue surprises of -33.33% and -97.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo Finance Fri, 08 May 2026

CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates

CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -23.33% and +80.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo Finance Mon, 27 Apr 2026

Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal

Ligand Pharmaceuticals snatched up Xoma Royalty in a deal worth $739 million, the companies said Monday as both biotech stocks jumped.

XOMA — Frequently Asked Questions

What is the current share price of XOMA Royalty Corp (XOMA)?

As of 2026-09-07 16:24 PDT, XOMA Royalty Corp (XOMA) trades at $40.17 on NasdaqGM. Its 52-week range is $40.17 to $40.17.

What is the market capitalisation of XOMA?

XOMA Royalty Corp (XOMA) has a market capitalisation of $710.16M on NasdaqGM.

What is the P/E ratio of XOMA?

XOMA trades at a trailing price-to-earnings (P/E) ratio of 25.59. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.15.

What is the return on equity (ROE) of XOMA?

XOMA has a return on equity (ROE) of 34.23%. Its return on capital employed (ROCE) is 18.85%.

Is XOMA a good stock to buy?

This page provides a data-driven analysis of XOMA Royalty Corp (XOMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space